# Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa

> **NCT02022020** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 220 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02022020
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2017-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02022020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02022020, "Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT02022020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*